Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer

International Journal of Biological Markers

Volumn 15, Issue 1, 2000, Pages 84-89

  Kos, J ^a   Werle, B ^b   Lah, T ^c   Brunner, N ^d  

^a JO EF STEFAN INSTITUTE   (Slovenia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^d FINSEN LABORATORY   (Denmark)

Author keywords

Cancer; Cathepsins; Cystatins; Prognosis; Serum; Stefins

Indexed keywords

CATHEPSIN B; CATHEPSIN H; CATHEPSIN L; CYSTATIN C; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; STEFIN A; STEFIN B;

BLOOD LEVEL; BRAIN CANCER; BREAST CANCER; CANCER; CANCER INVASION; CANCER SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; CORRELATION FUNCTION; EXTRACELLULAR FLUID; HEAD CANCER; HUMAN; LUNG CANCER; MELANOMA; METASTASIS; NECK CANCER; PROGNOSIS; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0034128337     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080001500116     Document Type: Conference Paper

References (47)

1. Uchiyama Y, Waguri S, Sato N, Watanabe T, Ishido K, Kominami E. Cell and tissue distribution of lysosomal cysteine proteinases, cathepsins B, H and L, and their biological roles. Acta Histochem Cytochem 1994; 27: 287-308.
2. Kos J, Lah T. Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncology Reports 1998; 5: 1349-61.
3. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 1997; 378: 141-50.
4. Sloane BF, Moin K, Lah TT. Lysosomal enzymes and their endogenous inhibitors in neoplasia. In: Pretlow TG, Pretlow TP, eds. Biochemical and molecular aspects of selected cancers. New york: Academic Press, 1994; 411-66.
5. Keppler D, Sloane BF. Cathepsin B: Multiple enzyme forms from a single gene and their relation to cancer. Enzyme Protein 1996; 49: 94-105.
6. Strojnik T, Kos J, Židanik B, Golouh R, Lah T. Cathepsin B immunostaining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 1999; 5: 559-67.
7. Lah T, Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 1998; 379: 125-30.
8. Foekens J, Kos J, Peters HA, et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J Clin Oncol 1998; 16: 1013-21.
9. Werle B, Lotterle H, Schanzenbacher U, et al. Immunochemical analysis of cathepsin B in lung tumors: an independent prognostic factor for squamous cell carcinoma patients. Br J Cancer 1999; 81: 510-9.
10. Schweiger A, Staib A, Werle B, et al. Cysteine proteinase cathepsin H in tumors and sera of lung cancer patients: relation to prognosis and cigarette smoking. Br J Cancer 2000; in press.
11. Strojan P, Budihna M, Šmid L, et al. Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2000; in press.
12. Kos J, Nielsen HJ, Krašovec M, et al. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 1998; 4: 1511-6.
13. Kos J, Krašovec M, Cimerman N, Jorgen-Nielsen H, Christensen IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B and cystatin C in sera of patients with colorectal cancer: relation to prognosis. Clin Cancer Res 2000; in press.
14. Lah TT, Čerček M, Blejec A, Kos J, Gorodetsky E, Somers R, Daskal I. Cathepsin B as prognostic indicator in lymph-node negative breast cancinoma patients: Comparison with cathepsin D, cathepsin L and other clinical indicators. Clin Cancer Res 2000; in press.
15. Leto G, Tuminello, FM, Pizzolanti G, Montallo G, Soresi M, Gebbia N. Lysosomal cathepsins B and L and stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. Oncol 1997; 54: 79-83.
16. Nishida Y, Kohno K, Kawamata T, Morimitsu K, Kuwano M, Miyakawa I. Increased cathepsin L levels in serum in some patients with ovarian cancer: comparison with CA125 and CA72-4. Gynecol Oncol 1995; 56: 357-61.
17. Warwas M, Haczynska H, Gerber J, Nowak M. Cathepsin B-like activity as a serum tumor marker in ovarian carcinoma. Eur J Clin Chem Clin Biochem 1997; 35: 301-4.
18. Kos J, Štabuc B, Schweiger A, et al. Cathepsins B, H, L, and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 1997; 3: 1815-22.
19. Edwards D, Murphy G. Proteases - invasion and more. Nature 1998; 394: 527-8.
20. Kornfeld S. Lysosomal enzyme targeting. Biochem Soc Trans 1990; 18: 367-74.
21. Barrett A, Kirschke H. Cathepsin B, cathepsin H and cathepsin L. In: Lorand L, ed. Methods in enzymology, Vol. 80. New York: Academic Press, 1981; 535-61.
22. Kos J, Šmid A, Krašovec M, et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem 1995; 376: 401-5.
23. Zore I, Krašovec M, Cimerman N, et al. Cathepsin B/cystatin C complex levels in sera from healthy donors and patients with benign and malignant lung and colorectal diseases. Submitted.
24. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40: 1921-6.
25. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997; 43: 1016-22.
26. Cimerman N, Meško Brguljan P, Krašovec M, Šuškovič S, Kos J. Circadian characteristics of cathepsins B, H, L, and stefins A and B, potential markers for disease, in normal sera. Clin Chim Acta 1999; 282: 211-8.
27. Cimerman N, Meško Brguljan P, Krašovec M, Šuškovič S, Kos J. Circadian characteristics of cystatin C in normal sera. Clin Chem Acta 2000; in press.
28. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C by automated immunoassay: A more sensitive marker of changes in GFR than serum creatinine. Kidney International 1995; 47: 312-8.
29. Kos J, Štabuc B, Cimerman N, Brunner N. Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression. Clin Chem 1998; 44: 2556-7.
30. Norlund L, Grubb A, Fex G, et al. The increase of plasma homocysteine concentrations with age is partly due to the deterioration of renal function as determined by plasma cystatin C. Clin Chem Lab Med 1998; 36: 175-8.
31. Luethgens K, Gabrijelčič D, Turk V, Ebert W, Trefz G, Lah T. Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients. Cancer Detection and Prevention 1993; 17: 387-97.
32. Lah TT, Kokalj-Kunovar M, Kastelic L, et al. Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett 1991; 61: 243-53.
33. Gabrijelčič D, Svetic B, Spaić D, et al. Cathepsins B, H and L in human breast carcinoma. Eur J Clin Chem Clin Biochem 1992; 30: 69-74.
34. Makarewicz R, Drewa G, Szymanski W, Skonieczna Makarewicz I. Cathepsin B in predicting the extent of cervix carcinoma. Neoplasma 1995; 42: 21-4.
35. Leto G, Tuminello FM, Pizzolanti G, et al. Lysosomal aspartic and cysteine proteinase serum level in patients with pancreatic cancer or pancreatitis. Pancreas 1997; 14: 22-7.
36. Dufek V, Jirasek V, Kral V, Matous B, Drazma E. Changes in serum cathepsin B-like activity in patients with colorectal cancer. Neoplasma 1985; 32: 51-7.
37. Amiguet JA, Jimenez J, Monreal JI, et al. Serum proteolytic activities and antiproteases in human colorectal carcinoma. J Physiol Biochem 1998; 54: 9-13.
38. Krepela E, Kasafirek E, Novak K. Increased cathepsin B activity in human lung tumours. Neoplasma 1990; 32: 51-8.
39. Bhuvarahamurthy V, Govindasamy S. Extracellular matrix components and proteolytic enzymes in uterine cervical carcinoma. Mol Cell Biochem 1995; 144: 35-43.
40. Hirano T, Manabe T, Takeuchi S. Serum cathepsin B levels and urinary excretion of cathepsin B in the cancer patients with remote metastasis. Cancer Lett 1993; 70: 41-4.
41. Sier CFM, Casetta G, Verheijen JH, et al. Enhanced urinary gelatinase activities (MMP-2 and MMP-9) are associated with early stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 2000; in press.
42. Dengler R, Lah T, Gabrijelčič D, Turk V, Fritz H, Emmerich B. Detection of cathepsin B in tumor cytosol and urine of breast cancer patients. Biomed Biochim Acta 1991; 50: 555-60.
43. Strojan P, Budihna M, Šmid L, et al. Cathepsin H in squamous cell carcinoma of the head and neck. Radiol Oncol 1999; 33: 143-51.
44. Leto G, Tumminello FM, Resso A, Pizzolanti G, Bazen V, Gebia N. Cathepsin D activity levels in colorectal cancer: correlation with cathepsin B and L and other biological and clinical parameters. Int J Oncol 1994; 5: 509-15.
45. Siewinski M, Krecicki T, Jarmulowicz J, Berdowska I. Cysteine proteinase inhibitors in serum of patients with head and neck tumours. Diagn Oncol 1992; 2: 323-6.
46. Siewinski M, Gutowicz J, Kielan W, Bolanowski M. Cysteine peptidase inhibitors and activator(s) in urine of patients with colorectal cancer. Oncology 1994; 51: 446-9.
47. Mikulewicz W, Berdowska I, Jarmulowicz J, Siewinski M. Decrease in vivo of cysteine endopeptidases in blood of patients with tumors of the larynx. Anticancer Drugs 1993; 4: 341-4.